Specialization
Focus of research
Regulatory science, rare diseases, orphan drugs
-
Twenty-Four Years After the Launch of the EU Orphan Regulation: Analyzing Dutch Price Dynamics, Biosimilars, and Generics for Orphan Medicinal Products
van den Berg, S., Hollak, C. E., Timmers, L. & de Visser, S. J., May 2025, In: Value in Health. 28, 5, p. 692-698 7 p.Research output: Contribution to journal › Article* › Academic › peer-review
-
Application of four pricing models for orphan medicines: a case study for lumasiran
Rosenberg, N., Manders, E., van den Berg, S., Deesker, L. J., Garrelfs, S. F., de Visser, S. J., Groothoff, J. W. & Hollak, C. E. M., 1 Dec 2024, In: Orphanet journal of rare diseases. 19, 1, 485.Research output: Contribution to journal › Article* › Academic › peer-review
-
Reliable business case for repurposing of existing medicines requires key changes in government policies
de Visser, S. J., van den Berg, S., Mosterd, A. & Lo, D. C., 1 Sept 2024, In: Drug Discovery Today. 29, 9, 104096.Research output: Contribution to journal › Editorial* › Academic › peer-review
- All publications